Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Cutan Pathol ; 35(11): 1063-7, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18544066

ABSTRACT

Subcutaneous gamma/delta (gamma/delta) T-cell lymphoma is a rare lymphoma, characterized by its unique immunophenotype and clinical course. It has been shown to behave more aggressively than its counterpart bearing the alpha/beta receptor and has recently been removed from the subcutaneous panniculitis-like T-cell lymphoma category for this very reason. We present a case of a patient with a 15-year running diagnosis of panniculitis. Following these years of indolent behavior, the disease began an aggressive clinical course and she was diagnosed with gamma/delta T-cell lymphoma. Molecular analysis identified a T-cell clone, which through retrospective analysis, was also shown to be present in the patient's original biopsy material. We present this case as a rare example of initial indolent behavior in a lymphoma typically considered very aggressive.


Subject(s)
Cell Transformation, Neoplastic/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Panniculitis/pathology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Skin Neoplasms/pathology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/administration & dosage , Carboplatin/therapeutic use , Clone Cells , Cyclophosphamide/administration & dosage , Cyclophosphamide/therapeutic use , Doxorubicin/administration & dosage , Doxorubicin/therapeutic use , Etoposide/administration & dosage , Etoposide/therapeutic use , Fatal Outcome , Female , Humans , Ifosfamide/administration & dosage , Ifosfamide/therapeutic use , Lymphoma, T-Cell, Cutaneous/drug therapy , Lymphoma, T-Cell, Cutaneous/genetics , Lymphoma, T-Cell, Cutaneous/metabolism , Middle Aged , Prednisone/administration & dosage , Prednisone/therapeutic use , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , T-Lymphocytes/pathology , Vincristine/administration & dosage , Vincristine/therapeutic use
2.
Transplantation ; 81(3): 418-22, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16477229

ABSTRACT

BACKGROUND: Composite tissue allotransplantation (CTA) is a recently introduced option for limb replacement and reconstruction of other nonreconstructible tissue defects. As with recipients of other allotransplants, CTA recipients can experience rejection episodes that are presumed to be mediated by immune mechanisms similar to those affecting solid organ grafts. However, a systematic examination of this process has not been performed, and there are no standardized criteria for the description of severity or type of rejection. METHODS: We collected biopsies from human limb allografts and abdominal walls in various stages of rejection for histological and immunohistochemical analysis to formulate a CTA rejection scheme. Biopsies were ranked by severity and reproducibility of the system was tested using a second set of biopsies. Tissue slides were examined blindly by three pathologists and the nonparametric Kendall coefficient of concordance (W) was used to assess the amount of agreement among the pathologists in their classification grades. RESULTS: Rejection initially appeared as a perivascular infiltrate progressing to involve the dermis. Arteritis was observed only in the medium to large size arteries of the subcutis. Myositis was seen occasionally. Perineural involvement without frank neuritis was present in advanced rejection. The infiltrate was predominantly CD4+ in milder cases and CD8+ in advanced cases. HLA-DR was minimally expressed in keratinocytes even in severe rejection. Kendall's W was 0.9375 (p< or =0.0001). CONCLUSIONS: Based on this survey, we proposed an initial classification system for acute rejection in the skin of a CTA and demonstrated that this system is easily reproduced by independent pathologists.


Subject(s)
Extremities/transplantation , Graft Rejection/classification , Graft Rejection/pathology , Skin/pathology , Tissue Transplantation , Antigens, Surface/analysis , Graft Rejection/immunology , Humans , Skin/immunology
3.
Biol Blood Marrow Transplant ; 12(1): 31-47, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16399567

ABSTRACT

This consensus document provides an update for pathologists and clinicians about the interpretation of biopsy results and use of this information in the management of hematopoietic cell transplantation patients. Optimal sampling and tissue preparation are discussed. Minimal criteria for the diagnosis of graft-versus-host disease (GVHD) are proposed, together with specific requirements for the diagnosis of chronic GVHD. Four final diagnostic categories (no GVHD, possible GVHD, consistent with GVHD, and definite GVHD) reflect the integration of histopathology with clinical, laboratory, and radiographic information. Finally, the Working Group developed a set of worksheets to facilitate communication of clinical information to the interpreting pathologist and to aid in clinicopathologic correlation studies. Forms are available at . The recommendations of the Working Group represent a consensus opinion supplemented by evaluation of available peer-reviewed literature. Consensus recommendations and suggested data-capture forms should be validated in prospective clinicopathologic studies.


Subject(s)
Clinical Trials as Topic/standards , Graft vs Host Disease/pathology , Hematopoietic Stem Cell Transplantation/adverse effects , Biopsy , Chronic Disease , Disease Management , Graft vs Host Disease/diagnosis , Humans , National Institutes of Health (U.S.) , Pathology/standards , Practice Guidelines as Topic , United States
4.
Transplantation ; 80(12): 1676-80, 2005 Dec 27.
Article in English | MEDLINE | ID: mdl-16378060

ABSTRACT

BACKGROUND: Composite tissue allotransplantation (CTA) is a recently introduced option for limb replacement and reconstruction of other nonreconstructible tissue defects. As with recipients of other allotransplants, CTA recipients can experience rejection episodes that are presumed to be mediated by immune mechanisms similar to those affecting solid organ grafts. However, a systematic examination of this process has not been performed, and there are no standardized criteria for the description of severity or type of rejection METHODS: We collected biopsies from human limb allografts and abdominal walls in various stages of rejection for histological and immunohistochemical analysis to formulate a CTA rejection scheme. Biopsies were ranked by severity and reproducibility of the system was tested using a second set of biopsies. Tissue slides were examined blindly by three pathologists and the nonparametric Kendall coefficient of concordance (W) was used to assess the amount of agreement among the pathologists in their classification grades. RESULTS: Rejection initially appeared as a perivascular infiltrate progressing to involve the dermis. Arteritis was observed only in the medium to large size arteries of the subcutis. Myositis was seen occasionally. Perineural involvement without frank neuritis was present in advanced rejection. The infiltrate was predominantly CD4+ in milder cases and CD8+ in advanced cases. HLA-DR was minimally expressed in keratinocytes even in severe rejection. Kendall's W was 0.9375 (p

Subject(s)
Graft Rejection/pathology , Organ Transplantation/pathology , Skin Diseases/pathology , Transplantation, Homologous/pathology , Acute Disease , Arteritis/pathology , Fibrosis/pathology , Humans , Necrosis , Organ Transplantation/classification , Transplantation, Homologous/classification
5.
J Am Acad Dermatol ; 52(4): 583-8, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15793506

ABSTRACT

BACKGROUND: Vitamin A derivatives modulate the inflammatory phase in wound healing. Retinoic acid can restore decreased tensile strength and collagen content in steroid- or diabetes-impaired wounds. It is hypothesized that retinoic acid can lead to accelerated healing with improved breaking strength in unimpaired incisional wounds. MATERIALS AND METHODS: Skin incisions were made in 45 CD-1 mice. The sutured wounds were treated once daily with topical all-trans-retinoic acid 0.1% (n = 15), vehicle ointment (n = 15), or left untreated (n = 15). Skin biopsies at 1-, 2-, and 3-week intervals were examined using hematoxylin and eosin (H&E), Masson's trichrome, and immunoperoxidase staining methods. Wound breaking strength was determined by biomechanical analysis. RESULTS: Incisions treated with retinoic acid exhibited a significantly reduced breaking strength at week 1 when compared to the vehicle and control group. Histologic examination showed a prolonged inflammatory reaction with abundant deposition of granulation tissue. Despite an increased fibroplastic proliferation in the tretinoin-treated wounds, the production of collagen was diminished. CONCLUSIONS: Topical retinoic acid does not enhance the healing of unimpaired incisional wounds. The inadequate tensile strength in the early phase of the healing process is possibly the result of an increased dermal inflammatory response and the decreased collagen content. Although these adverse effects disappeared by 3 weeks postwounding, we found no discernible benefit of supplemental retinoic acid in unimpaired wounds.


Subject(s)
Tretinoin/administration & dosage , Wound Healing/drug effects , Administration, Topical , Animals , Collagen/analysis , Disease Models, Animal , Male , Mice , Skin/anatomy & histology , Skin/chemistry , Tensile Strength/drug effects , Tretinoin/therapeutic use , Wounds, Stab/drug therapy , Wounds, Stab/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...